02 Jan Predicting the effects of drugs that affect changes in kinetic parameters
MavacamtenMavacamten (MYK-461) was recently approved by FDA as an allosteric inhibitor of sarcomeric myosins since it had been successfully used in clinical trials for treatment of obstructive HCM. Mavacamten negative inotropic action is likely mediated by the shift of detached motor heads towards auto inhibited...